Designed to increase the efficiency and quality of vaccine discovery, the end-to-end enterprise platform supports the full development process for novel vaccines and enables faster testing, simplified production, and reduced costs. In addition to classical vaccine R&D approaches, it supports novel vaccine technologies such as synthetic self-amplifying mRNA, which accelerates vaccine development by utilizing synthetic and cell-free processes. This paves the way for the development of novel vaccines, even for antigens that are extremely difficult to produce and formulate. A dedicated, purpose-built enterprise software platform, it automates complex processes, supports teamwork in a division of labor environment, and integrates new R&D technologies and workflows. In particular, it optimizes vaccine bioprocess development, monitors vaccine product quality, and ensures data integrity and compliance
Reduce timelines across cell line development, upstream and downstream process development, formulation, and analytical development.Choose Your Application
QbD. Clone selection. Media optimization. CQA monitoring. Optimizing DSP unit operations. Formulation screening. Genedata Bioprocess® acts as an integrated, end-to-end workflow backbone that provides purpose-built functionalities for all applications across bioprocess development.